Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress Jun 14, 2024 7:30am EDT
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jun 03, 2024 4:30pm EDT
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 31, 2024 8:00am EDT
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 May 06, 2024 4:30pm EDT
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 Mar 18, 2024 4:30pm EDT
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option Jan 31, 2024 4:01pm EST
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical Jan 26, 2024 8:00am EST
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting Dec 09, 2023 6:30pm EST
